AdvanCell · Series D
Senior Translational Scientist
Translational Research Institute, Brisbane, QLD, AU
Posted 25 days ago· Oct 27

Biotechnology, Clinical Trials, Oncology, Pharmaceutical
AdvanCell raised $315M in a Series D announced on Jul 15, 2026, led by Eli Lilly, Alpha Wave Global, Catalio Capital Management, Bain Capital Life Sciences, SV Health Investors. Since then it has posted 14 roles (6 still open), the first on the day of the announcement. With 6 open roles it is hiring more than 6% of the 67 Series D+ startups on JustBacked (median: 48). In total it has raised $453M over 5 rounds from 22 investors.
From AdvanCell's own hiring system, by posting date. Tracked since Aug 21, 2026; roles that closed before then aren't counted.
AdvanCell develops targeted alpha radiopharmaceutical therapies for cancer and supports their development and manufacturing.
Radiation that reaches only the tumor becomes the default cancer treatment, and older therapies start to look dated. AdvanCell, a Sydney radiopharmaceutical developer, is building that with targeted alpha therapies, and owning both development and manufacturing could make it a supplier drug makers rely on. Eli Lilly and Bain Capital Life Sciences sit among the leads on a $315M Series D, bringing its total to $453M across 5 rounds.
JustBacked's take, based on AdvanCell's own site and its funding and hiring data.
Hiring velocity
Where they're hiring
AdvanCell · Series D
Translational Research Institute, Brisbane, QLD, AU
Posted 25 days ago· Oct 27
AdvanCell · Series D
Richlands, Brisbane, QLD, AU
Posted 64 days ago· Sep 18
AdvanCell · Series D
Boston, MA
$170K–$220K
Posted 77 days ago· Sep 4
AdvanCell · Series D
Boston, MA
$170K–$220K
Posted 77 days ago· Sep 4
AdvanCell · Series D
Andover, MA
$170K–$220K
Posted 112 days ago· Jul 31
AdvanCell · Series D
Richlands, Brisbane, QLD, AU
Posted 129 days ago· Jul 15
Source: jobs.lever.co, checked daily.